仟源醫藥(300254.SZ)及子公司4個藥品擬中標第三批集採
格隆匯8月21日丨仟源醫藥(300254.SZ)宣佈,2020年8月20日,公司及子公司海力生製藥、嘉逸醫藥已通過仿製藥質量和療效一致性評價的藥品鹽酸氨溴索分散片、鹽酸氟西汀膠囊、鹽酸坦索羅辛緩釋膠囊和阿哌沙班片參加了聯合採購辦公室組織的第三批全國藥品集中採購投標工作。根據聯採辦發佈的全國藥品集中採購擬中選結果公示,上述藥品均擬中標該次集採。
其中,仟源醫藥鹽酸氨溴索分散片(30mg)及鹽酸氟西汀膠囊(20mg)擬中標數量分別為158.0367萬盒及35.97萬盒,價格分別為5.25元/盒及39.8元/盒;海力生製藥鹽酸坦索羅辛緩釋膠囊(0.2mg)擬中標數量為553.619萬盒,價格為8.97元/盒;嘉逸醫藥阿哌沙班片(2.5mg)擬中標數量為0.5812萬盒,價格為99元/盒。
公司及子公司該次擬中標的產品鹽酸坦索羅辛緩釋膠囊、鹽酸氨溴索分散片2019年度銷售收入分別為1.47億元和4701.52萬元,分別佔公司2019年度營業收入的12.96%和4.15%;鹽酸氟西汀膠囊2019年無銷售收入;阿哌沙班片於近日才收到國家藥品監督管理局簽發的《藥品註冊批件》。
該次集採是國家組織的第三批藥品集中帶量採購,包含全國31個省市自治區及新疆建設兵團,約定採購量,並在全國範圍同步實施。在執行上要求醫療機構優先使用集採中選品種,並確保完成約定採購量。若公司後續簽訂採購合同並實施後,將有利於進一步擴大相關產品的銷售,提高市場佔有率,促進公司有關產品市場的開拓,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.